PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
Turnover
16.67%
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
-6.83%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$116M
AUM Growth
-$26.7M
(-19%)
Cap. Flow
-$11M
Cap. Flow
% of AUM
-9.44%
Top 10 Holdings %
Top 10 Hldgs %
31.93%
Holding
117
New
6
Increased
16
Reduced
64
Closed
5
Avg Time Held
2.6
years
Top 10 Avg Time Held
1.3
years
Top 20 Avg Time Held
1.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HTGM
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
|
+$1.97M |
| 2 |
Exagen
XGN
|
+$1.41M |
| 3 |
BioLife Solutions
BLFS
|
+$1.1M |
| 4 |
Avinger, Inc. Common Stock
AVGR
|
+$1.08M |
| 5 |
Castle Biosciences
CSTL
|
+$619K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Magnite
MGNI
|
+$2.1M |
| 2 |
Digital Turbine
APPS
|
+$1.92M |
| 3 |
CryoPort
CYRX
|
+$1.22M |
| 4 |
Expeditors International
EXPD
|
+$797K |
| 5 |
Veracyte
VCYT
|
+$565K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.68% |
| 2 | Technology | 13.69% |
| 3 | Communication Services | 6.62% |
| 4 | Industrials | 5.98% |
| 5 | Consumer Staples | 3.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Vericel Corp
VCEL
$2.06B
| $6.04M | 5.21% |
398,997
-27,953
| -7% | -$489K |
2014 Q3
20 quarters
|
|
2
NeoGenomics
NEO
$2.17B
| $5.01M | 4.32% |
262,300
-17,400
| -6% | -$408K |
2013 Q2
25 quarters
|
|
3
Axogen
AXGN
$2.06B
| $3.99M | 3.44% |
319,775
-20,000
| -6% | -$329K |
2013 Q3
24 quarters
|
|
4
Natera
NTRA
$56.9B
| $3.57M | 3.08% |
108,900
-17,600
| -14% | -$520K |
2018 Q2
5 quarters
|
|
|
5
Veracyte
VCYT
$3.5B
| $3.56M | 3.06% |
148,130
-21,250
| -13% | -$565K |
2018 Q1
6 quarters
|
|
|
CSII
6
DELISTED
Cardiovascular Systems, Inc.
CSII
| $3.27M | 2.82% |
68,766
-7,634
| -10% | -$359K |
2013 Q2
25 quarters
|
|
7
Idexx Laboratories
IDXX
$41.7B
| $3.09M | 2.66% |
11,350
| – | – |
2013 Q3
24 quarters
|
|
|
8
Magnite
MGNI
$3.42B
| $2.94M | 2.53% |
337,383
-239,717
| -42% | -$2.1M |
2018 Q2
5 quarters
|
|
9
Abbott
ABT
$178B
| $2.9M | 2.5% |
34,611
-1,050
| -3% | -$89.2K |
2014 Q1
22 quarters
|
|
10
OptimizeRx
OPRX
$156M
| $2.69M | 2.32% |
185,823
-26,970
| -13% | -$417K |
2018 Q2
5 quarters
|
|
11
CareDx
CDNA
$3.35B
| $2.5M | 2.15% |
110,333
-16,417
| -13% | -$455K |
2017 Q3
8 quarters
|
|
12
Rockwell Medical
RMTI
$30.9M
| $2.31M | 1.99% |
7,600
-1,062
| -12% | -$326K |
2013 Q2
25 quarters
|
|
13
Microsoft
MSFT
$3.96T
| $2.28M | 1.96% |
16,385
-1,250
| -7% | -$172K |
2014 Q1
22 quarters
|
|
14
Pfizer
PFE
$166B
| $2.1M | 1.81% |
61,596
+527
| +0.9% | +$19.2K |
2013 Q2
25 quarters
|
|
15
LeMaitre Vascular
LMAT
$1.89B
| $2.09M | 1.8% |
61,130
| – | – |
2017 Q1
10 quarters
|
|
16
Eli Lilly
LLY
$1.08T
| $2.07M | 1.78% |
18,510
-1,725
| -9% | -$192K |
2013 Q2
25 quarters
|
|
|
IDXG
17
DELISTED
Interpace Biosciences, Inc. Common Stock
IDXG
| $1.88M | 1.62% |
236,039
+43,314
| +22% | +$338K |
2018 Q3
4 quarters
|
|
18
Sensus Healthcare
SRTS
$47.1M
| $1.86M | 1.6% |
309,881
-58,655
| -16% | -$341K |
2018 Q2
5 quarters
|
|
|
19
DELISTED
BioLife Solutions
BLFS
| $1.85M | 1.59% |
111,250
+58,500
| +111% | +$1.1M |
2014 Q2
21 quarters
|
|
20
DELISTED
Cantaloupe
CTLP
| $1.71M | 1.47% |
232,610
-57,750
| -20% | -$415K |
2014 Q1
22 quarters
|
|
|
21
Digital Turbine
APPS
$1.16B
| $1.68M | 1.45% |
260,300
-309,000
| -54% | -$1.92M |
2015 Q1
18 quarters
|
|
|
22
CryoPort
CYRX
$843M
| $1.68M | 1.45% |
102,600
-60,920
| -37% | -$1.22M |
2016 Q1
14 quarters
|
|
23
AT&T
T
$158B
| $1.67M | 1.44% |
58,338
-10,129
| -15% | -$268K |
2015 Q3
16 quarters
|
|
24
ANI Pharmaceuticals
ANIP
$1.61B
| $1.66M | 1.43% |
22,783
-7,017
| -24% | -$525K |
2017 Q1
10 quarters
|
|
25
Target
TGT
$70.6B
| $1.56M | 1.35% |
14,640
-1,000
| -6% | -$95.1K |
2017 Q4
7 quarters
|
|
Similar funds
AA
WA
AC
BCVI
HAP
RHIG
CWM
SI
Perkins Capital Management's Q3 2019 Portfolio in Review
As of Q3 2019, Perkins Capital Management held 117 positions worth $116M, down 19% from $143M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Perkins Capital Management withdrew a net $11M in Q3 2019, closing 5 positions and reducing 64 holdings. Its most notable exit was Expeditors International, an estimated $797K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 63% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Perkins Capital Management opened a new position in Exagen worth $1.35M.
- Perkins Capital Management's largest Q3 2019 buy was Exagen: 87,450 shares worth $1.35M.
- Perkins Capital Management added most to HTG Molecular Diagnostics, Inc. Common Stock in Q3 2019, an estimated $1.97M increase.
- Perkins Capital Management's biggest Q3 2019 reduction was Magnite, cutting an estimated $2.1M.
- Perkins Capital Management fully exited Expeditors International in Q3 2019, selling an estimated $797K.
- Perkins Capital Management's ten largest holdings make up 32% of its $116M portfolio in Q3 2019.
- Perkins Capital Management opened 6 new positions and closed 5 in Q3 2019.
- Perkins Capital Management's portfolio value fell 19% quarter-over-quarter to $116M.
Based on Perkins Capital Management's 13F filing for Q3 2019, filed 23 Oct 2019.